CommentTivantinib for advanced hepatocellular carcinoma: is MET still a viable target?
References (9)
- et al.
Tivantinib for second-line treatment of advanced MET-high hepatocellular carcinoma (METIV-HCC): a phase 3, randomised, placebo-controlled study
Lancet Oncol
(2018) - et al.
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Lancet Oncol
(2013) - et al.
Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
Diagn Pathol
(2015) - et al.
Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review
Oncotarget
(2017)
There are more references available in the full text version of this article.
Cited by (12)
Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021
2022, Expert Opinion on Investigational DrugsResponse to crizotinib in a patient with MET-amplified hepatocellular carcinoma
2021, Hepatology ResearchMET canonical transcript expression is a predictive biomarker for chemo-sensitivity to MET-inhibitors in hepatocellular carcinoma cell lines
2021, Journal of Cancer Research and Clinical OncologyHepatocellular carcinoma
2019, Oncology in the Precision Medicine Era: Value-Based Medicine
© 2018 Elsevier Ltd. All rights reserved.